RxDoctor Payments Data

Ahmed Morales Jorge, MD

Gastroenterology · Coto Laurel, PRNPI 1265546592

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $163,472 of the $213,936 with a category attached, or 76.4%. 17 manufacturers reported payments, led by AbbVie at 42.7% of the total. Among gastroenterology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$213,936in general payments, 2019–2025

Across 357 payments — averaging $599.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$91K
  • E.r. Squibb & Sons, L.L.C.$49K
  • Johnson & Johnson$26K
  • Lilly USA, LLC$24K
  • Pfizer$17K
  • Merck$5K
  • plus $3K from 11 others

What the payments were for

  • Consulting fees$25,62812%
  • Speaking & faculty fees$163,47276%
  • Travel & lodging$13,2786%
  • Food & beverage$11,4115%
  • Education$1480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie171$91,368
E.r. Squibb & Sons, L.L.C.52$48,529
Johnson & Johnson(2 entities)44$25,728
Lilly USA, LLC21$24,034
Pfizer10$16,542
Merck7$4,771
Bristol Myers Squibb2$1,200
PBG Puerto Rico LLC13$472
Takeda Pharmaceuticals U.S.A., Inc.18$438
Pfizer Pharmaceuticals LLC3$181
Organon6$177
Gilead3$161
Johnson And Johnson International2$149
Madrigal Pharmaceuticals1$101
Amgen2$43
Sanofi1$22
Eli Lilly Export S.A. Puerto Rico Branch1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$213,936 in reported general payments places this provider in the 95th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,618
Medicare patients
30
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab28$757,820
Skyrizi On-BodyRisankizumab-Rzaa18$380,907
LinzessLinaclotide518$289,421
Humira(Cf) PenAdalimumab27$187,286
XeljanzTofacitinib Citrate18$103,420
RinvoqUpadacitinib13$88,435
Mesalamine55$51,015
XifaxanRifaximin15$47,102
Budesonide ErBudesonide36$30,873
SuprepSodium, Potassium,mag Sulfates175$20,651
Dexlansoprazole DrDexlansoprazole77$17,889
MotegrityPrucalopride Succinate29$15,462
Sucralfate60$11,334
Lubiprostone71$10,238
CholestyramineCholestyramine (With Sugar)65$9,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$25,728$757,82028 claims
AbbVieLinzess, Rinvoq$91,368$377,856531 claims
PfizerXeljanz$16,542$103,42018 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant$438$24,04049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in Coto Laurel

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →